Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST: Brolucizumab for Persistent Diabetic Macular Edema
NCT06498050Phase 4Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of brolucizumab in diabetic macular edema (DME), sponsored by Guangdong Provincial People's Hospital. Started Jul 2024; status: active, not recruiting.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06498050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498050.